Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4)
The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational E...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kramer Schmidt, Lotte [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment - 2013, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:97 ; year:2019 ; pages:59-67 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jsat.2018.11.004 |
|---|
| Katalog-ID: |
ELV045240558 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV045240558 | ||
| 003 | DE-627 | ||
| 005 | 20230624114215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190205s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jsat.2018.11.004 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000521.pica |
| 035 | |a (DE-627)ELV045240558 | ||
| 035 | |a (ELSEVIER)S0740-5472(18)30311-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Kramer Schmidt, Lotte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) |
| 264 | 1 | |c 2019 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS). | ||
| 700 | 1 | |a Andersen, Kjeld |4 oth | |
| 700 | 1 | |a Nielsen, Anette Søgaard |4 oth | |
| 700 | 1 | |a Moyers, Theresa B. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |d 2013 |g Amsterdam [u.a.] |w (DE-627)ELV011527242 |
| 773 | 1 | 8 | |g volume:97 |g year:2019 |g pages:59-67 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jsat.2018.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_30 | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 97 |j 2019 |h 59-67 |g 9 | ||
| author_variant |
s l k sl slk |
|---|---|
| matchkey_str |
kramerschmidtlotteandersenkjeldnielsenan:2019----:esnlandrmesrnfdltwtteoiainlneveigr |
| hierarchy_sort_str |
2019 |
| bklnumber |
44.40 |
| publishDate |
2019 |
| allfields |
10.1016/j.jsat.2018.11.004 doi GBV00000000000521.pica (DE-627)ELV045240558 (ELSEVIER)S0740-5472(18)30311-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Kramer Schmidt, Lotte verfasserin aut Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS). Andersen, Kjeld oth Nielsen, Anette Søgaard oth Moyers, Theresa B. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:97 year:2019 pages:59-67 extent:9 https://doi.org/10.1016/j.jsat.2018.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 97 2019 59-67 9 |
| spelling |
10.1016/j.jsat.2018.11.004 doi GBV00000000000521.pica (DE-627)ELV045240558 (ELSEVIER)S0740-5472(18)30311-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Kramer Schmidt, Lotte verfasserin aut Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS). Andersen, Kjeld oth Nielsen, Anette Søgaard oth Moyers, Theresa B. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:97 year:2019 pages:59-67 extent:9 https://doi.org/10.1016/j.jsat.2018.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 97 2019 59-67 9 |
| allfields_unstemmed |
10.1016/j.jsat.2018.11.004 doi GBV00000000000521.pica (DE-627)ELV045240558 (ELSEVIER)S0740-5472(18)30311-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Kramer Schmidt, Lotte verfasserin aut Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS). Andersen, Kjeld oth Nielsen, Anette Søgaard oth Moyers, Theresa B. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:97 year:2019 pages:59-67 extent:9 https://doi.org/10.1016/j.jsat.2018.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 97 2019 59-67 9 |
| allfieldsGer |
10.1016/j.jsat.2018.11.004 doi GBV00000000000521.pica (DE-627)ELV045240558 (ELSEVIER)S0740-5472(18)30311-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Kramer Schmidt, Lotte verfasserin aut Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS). Andersen, Kjeld oth Nielsen, Anette Søgaard oth Moyers, Theresa B. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:97 year:2019 pages:59-67 extent:9 https://doi.org/10.1016/j.jsat.2018.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 97 2019 59-67 9 |
| allfieldsSound |
10.1016/j.jsat.2018.11.004 doi GBV00000000000521.pica (DE-627)ELV045240558 (ELSEVIER)S0740-5472(18)30311-8 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.40 bkl Kramer Schmidt, Lotte verfasserin aut Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS). Andersen, Kjeld oth Nielsen, Anette Søgaard oth Moyers, Theresa B. oth Enthalten in Elsevier Science Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment 2013 Amsterdam [u.a.] (DE-627)ELV011527242 volume:97 year:2019 pages:59-67 extent:9 https://doi.org/10.1016/j.jsat.2018.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 44.40 Pharmazie Pharmazeutika VZ AR 97 2019 59-67 9 |
| language |
English |
| source |
Enthalten in Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment Amsterdam [u.a.] volume:97 year:2019 pages:59-67 extent:9 |
| sourceStr |
Enthalten in Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment Amsterdam [u.a.] volume:97 year:2019 pages:59-67 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Pharmazie Pharmazeutika |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| authorswithroles_txt_mv |
Kramer Schmidt, Lotte @@aut@@ Andersen, Kjeld @@oth@@ Nielsen, Anette Søgaard @@oth@@ Moyers, Theresa B. @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011527242 |
| dewey-sort |
3610 |
| id |
ELV045240558 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045240558</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624114215.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jsat.2018.11.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000521.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045240558</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0740-5472(18)30311-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kramer Schmidt, Lotte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS).</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Andersen, Kjeld</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nielsen, Anette Søgaard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moyers, Theresa B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011527242</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:97</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:59-67</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jsat.2018.11.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_30</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="j">Pharmazie</subfield><subfield code="j">Pharmazeutika</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">97</subfield><subfield code="j">2019</subfield><subfield code="h">59-67</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| author |
Kramer Schmidt, Lotte |
| spellingShingle |
Kramer Schmidt, Lotte ddc 610 bkl 44.40 Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) |
| authorStr |
Kramer Schmidt, Lotte |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011527242 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.40 bkl Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) |
| topic |
ddc 610 bkl 44.40 |
| topic_unstemmed |
ddc 610 bkl 44.40 |
| topic_browse |
ddc 610 bkl 44.40 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k a ka a s n as asn t b m tb tbm |
| hierarchy_parent_title |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| hierarchy_parent_id |
ELV011527242 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011527242 |
| title |
Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) |
| ctrlnum |
(DE-627)ELV045240558 (ELSEVIER)S0740-5472(18)30311-8 |
| title_full |
Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) |
| author_sort |
Kramer Schmidt, Lotte |
| journal |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| journalStr |
Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
59 |
| author_browse |
Kramer Schmidt, Lotte |
| container_volume |
97 |
| physical |
9 |
| class |
610 VZ 44.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kramer Schmidt, Lotte |
| doi_str_mv |
10.1016/j.jsat.2018.11.004 |
| dewey-full |
610 |
| title_sort |
lessons learned from measuring fidelity with the motivational interviewing treatment integrity code (miti 4) |
| title_auth |
Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) |
| abstract |
The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS). |
| abstractGer |
The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS). |
| abstract_unstemmed |
The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS). |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_20 GBV_ILN_30 GBV_ILN_40 |
| title_short |
Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4) |
| url |
https://doi.org/10.1016/j.jsat.2018.11.004 |
| remote_bool |
true |
| author2 |
Andersen, Kjeld Nielsen, Anette Søgaard Moyers, Theresa B. |
| author2Str |
Andersen, Kjeld Nielsen, Anette Søgaard Moyers, Theresa B. |
| ppnlink |
ELV011527242 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.jsat.2018.11.004 |
| up_date |
2024-07-06T16:59:19.946Z |
| _version_ |
1803849731879731200 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045240558</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624114215.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jsat.2018.11.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000521.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045240558</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0740-5472(18)30311-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kramer Schmidt, Lotte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Motivational Interviewing Treatment Integrity code (MITI) measures fidelity to, and the quality of, Motivational Interviewing (MI), and can also be used when MI is combined with other treatment methods. The current study presents a fidelity measurement with the MITI 4.2.1, in both Motivational Enhancement Therapy sessions and the combined Community Reinforcement Approach-Senior (CRAS).</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Andersen, Kjeld</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nielsen, Anette Søgaard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moyers, Theresa B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011527242</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:97</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:59-67</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jsat.2018.11.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_30</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="j">Pharmazie</subfield><subfield code="j">Pharmazeutika</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">97</subfield><subfield code="j">2019</subfield><subfield code="h">59-67</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| score |
7.400529 |